NYSE:NVO • US6701002056
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NOVO-NORDISK A/S-SPONS ADR (NVO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2026-02-24 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2026-01-09 | CICC | Initiate | Outperform |
| 2025-12-08 | Argus Research | Downgrade | Buy -> Hold |
| 2025-11-28 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-11-25 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2025-11-24 | HSBC | Downgrade | Buy -> Hold |
| 2025-10-14 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2025-10-02 | HSBC | Upgrade | Hold -> Buy |
| 2025-09-29 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2025-09-17 | Berenberg | Upgrade | Hold -> Buy |
| 2025-08-19 | TD Cowen | Maintains | Buy -> Buy |
| 2025-08-05 | UBS | Downgrade | Buy -> Neutral |
| 2025-07-31 | HSBC | Downgrade | Buy -> Hold |
| 2025-07-30 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2025-04-17 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2025-01-08 | UBS | Upgrade | Sell -> Buy |
| 2024-12-23 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-11-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-10-17 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-10-10 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-19 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 232.261B 31.26% | 290.403B 25.03% | 309.064B 6.43% | 299.23B -3.18% | 312.367B 4.39% | 333.87B 6.88% | 352.071B 5.45% | 371.248B 5.45% | 386.046B 3.99% | 374.024B -3.11% | 357.765B -4.35% | |
| EBITDA YoY % growth | 114.111B 37.43% | 158.008B 38.47% | 149.64B -5.30% | 143.429B -4.15% | 147.276B 2.68% | 160.015B 8.65% | 167.906B 4.93% | 183.057B 9.02% | 190.49B 4.06% | 180.756B -5.11% | 180.637B -0.07% | |
| EBIT YoY % growth | 104.698B 38.36% | 138.901B 32.67% | 127.658B -8.09% | 124.292B -2.64% | 125.935B 1.32% | 137.809B 9.43% | 144.046B 4.53% | 156.188B 8.43% | 164.763B 5.49% | 153.286B -6.97% | 135.537B -11.58% | |
| Operating Margin | 45.08% | 47.83% | 41.30% | 41.54% | 40.32% | 41.28% | 40.91% | 42.07% | 42.68% | 40.98% | 37.88% | |
| EPS YoY % growth | 18.64 52.33% | 22.66 21.57% | 23.06 1.77% | 22.81 -1.09% | 24.23 6.22% | 28.40 17.24% | 25.60 -9.85% | 27.32 6.71% | 28.03 2.59% | 25.21 -10.07% | 22.62 -10.26% |
All data in DKK
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 5.90 -9.83% | 5.69 -4.71% | 5.42 20.19% | 6.29 4.09% |
| Revenue Q2Q % growth | 75.532B -3.27% | 73.68B -4.13% | 84.698B 12.97% | 88.696B 12.07% |
| EBITDA Q2Q % growth | 38.349B -10.02% | 38.147B -9.42% | 39.517B -1.46% | 29.864B -44.41% |
| EBIT Q2Q % growth | 34.205B -11.82% | 28.837B -13.79% | 26.485B 11.84% | 36.754B 15.81% |
All data in DKK
34 analysts have analysed NVO and the average price target is 57.95 USD. This implies a price increase of 50.43% is expected in the next year compared to the current price of 38.525.
NOVO-NORDISK A/S-SPONS ADR (NVO) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of NOVO-NORDISK A/S-SPONS ADR (NVO) is 5.9 USD and the consensus revenue estimate is 75.53B USD.
The number of analysts covering NOVO-NORDISK A/S-SPONS ADR (NVO) is 34.